| Identification | Back Directory | [Name]
SR17018 | [CAS]
2134602-45-0 | [Synonyms]
SR17018
CS-2685
SR1 7018;SR-17018;SR17018
2H-Benzimidazol-2-one, 5,6-dichloro-1-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1,3-dihydro- | [EINECS(EC#)]
218-362-5 | [Molecular Formula]
C19H18Cl3N3O | [MOL File]
2134602-45-0.mol | [Molecular Weight]
410.72 |
| Chemical Properties | Back Directory | [density ]
1.428±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:6.0(Max Conc. mg/mL);14.61(Max Conc. mM) | [form ]
A crystalline solid | [pka]
10.03±0.30(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C19H18Cl3N3O/c20-13-3-1-12(2-4-13)11-24-7-5-14(6-8-24)25-18-10-16(22)15(21)9-17(18)23-19(25)26/h1-4,9-10,14H,5-8,11H2,(H,23,26) | [InChIKey]
LAGUDYUGRSQDKS-UHFFFAOYSA-N | [SMILES]
C1(=O)N(C2CCN(CC3=CC=C(Cl)C=C3)CC2)C2=CC(Cl)=C(Cl)C=C2N1 |
| Hazard Information | Back Directory | [Uses]
SR17018 is an mu-opioid-receptor (MOR) agonist with an EC50 of 97 nM. | [Biological Activity]
Opioid analgesia is accompanied by side effects including tolerance, respiratory depression, constipation, and opioid induced hyperalgesia (OIH), which primarily mediated via the activation of μ receptors. Research suggest that the detrimental effects might be minimised by restricting β-arrestin2 recruitment to the μ receptor. SR17018 is a high-efficacy activator of G-protein signalling with limited capacity to stimulate β-arrestin2 recruitment largely through a non-competitive agonist action[1]. | [IC 50]
μ Opioid Receptor/MOR | [storage]
Store at -20°C | [References]
[1] Singleton, S., Dieterle, C., Walker, D. J., Runeberg, T., Oswald, A. S., Rosenqvist, G., Robertson, L., McCarthy, T., Sarkar, S., Baptista-Hon, D., & Hales, T. G. (2024). Activation of μ receptors by SR-17018 through a distinctive mechanism. Neuropharmacology, 258, Article 110093. https://doi.org/10.1016/j.neuropharm.2024.110093
|
|
| Company Name: |
xinguokeji Gold
|
| Tel: |
13120711461 |
| Website: |
|
|